Exact Sciences (NASDAQ: EXAS) is a prominent player in the molecular diagnostics industry, known for its innovative cancer screening products. The company has been making headlines recently due to a significant rally in its stock price. On November 20, 2025, Catherine Ramsey Schulte from Robert W. Baird set a price target of $105 for EXAS, while the stock was trading at $101.34, indicating a potential upside of approximately 3.61%.
The stock's recent surge of nearly 20% on November 20 can be attributed to Abbott Laboratories' announcement of a $21 billion all-cash deal to acquire Exact Sciences. This acquisition news has significantly boosted investor confidence, as highlighted by the stock's current price of $101.05, reflecting a 17.25% increase with a change of $14.87. The stock has seen fluctuations today, with a low of $100.95 and a high of $101.87, which is also its highest price in the past year.
Exact Sciences' market capitalization stands at approximately $19.15 billion, showcasing its substantial presence in the market. The trading volume for the stock today is notably high at 53.63 million shares, indicating strong investor interest. Over the past year, the stock has experienced a wide price range, with its lowest price being $38.81, demonstrating the volatility and growth potential of EXAS.
The acquisition by Abbott Laboratories is a significant development for Exact Sciences, as it positions the company for further growth and expansion in the molecular diagnostics sector. This strategic move is likely to enhance Exact Sciences' capabilities and market reach, making it a key player in the industry. The positive market reaction to the acquisition news reflects the confidence investors have in the future prospects of NASDAQ:EXAS.
